Home > Boards > US Listed > Biotechs > Durect (DRRX)

hmuneyTo be honest I was surprised to see

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
turning stone Member Profile
 
Followed By 6
Posts 376
Boards Moderated 0
Alias Born 03/24/09
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 5:08:19 PM
DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in ... PR Newswire (US) - 11/12/2019 8:45:00 AM
DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results PR Newswire (US) - 11/6/2019 5:47:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 3:37:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 4:21:37 PM
DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs PR Newswire (US) - 11/4/2019 4:05:00 PM
DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4 PR Newswire (US) - 10/30/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2019 1:00:03 PM
DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver... PR Newswire (US) - 10/21/2019 10:12:00 AM
DURECT to Present at Two Upcoming NASH Investor Conferences PR Newswire (US) - 10/17/2019 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/7/2019 3:30:55 PM
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Ph... PR Newswire (US) - 10/7/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/2/2019 3:31:06 PM
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIRĀ® for the Treatment of Post-Surgical Pain PR Newswire (US) - 10/2/2019 8:00:00 AM
DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference PR Newswire (US) - 9/26/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 10:48:26 AM
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis PR Newswire (US) - 9/17/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2019 1:37:50 PM
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Ut... PR Newswire (US) - 9/9/2019 9:29:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/6/2019 6:01:44 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/5/2019 2:44:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/4/2019 5:50:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 9/4/2019 5:28:35 PM
DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright PR Newswire (US) - 9/4/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2019 4:33:55 PM
turning stone   Friday, 09/06/19 10:23:44 PM
Re: hmuney post# 840
Post # of 885 
hmuney


To be honest I was surprised to see they moved the share price up toward the end of the day. I think the company would not be presenting on Monday at the conference if they had any thoughts of having a problem with any of their trials. Once again they will be getting their name out in front of some very influential people. This is a rather small company run by some very interesting people. If you haven't done so look over the background of these people. Yes they have had set backs but that usually goes with the territory in their kind of business. I come from a large family background in medicine and can fill your head with all types of stories. I have heavily researched this company and own a significant number of shares in it at a nice low entry level.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist